Crystalluria and urinary tract abnormalities associated with indinavir

Annals of Internal Medicine

Volumn 127, Issue 2, 1997, Pages 119-125

  Kopp, Jeffrey B ^a   Miller, Kirk D ^a   Mican, Jo Ann M ^a   Feuerstein, Irwin M ^a   Vaughan, Ellen ^a   Baker, Chandra ^a   Pannell, Lewis K ^a   Falloon, Judith ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; PROTEINASE INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; CRYSTALLURIA; DYSURIA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NEPHROLITHIASIS; PRIORITY JOURNAL; SYMPTOMATOLOGY; URINARY TRACT DISEASE;

EID: 0030793476     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-127-2-199707150-00004     Document Type: Article

References (21)

1. Bartlett JG. Protease inhibitors for HIV infection [Editorial]. Ann Intern Med. 1996;124:1086-8.
2. Corey L, Holmes KK. Therapy for human immunodeficiency virus infection - what have we learned? [Editorial] N Engl J Med. 1996;335:1142-4.
3. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. JAMA. 1997;277:145-53.
4. Tanouye E. Merck's rush to bring drug to market causes bottleneck. Wall Street Journal. 5 November 1996: A1, A6.
5. Gulick R, Mellors J, Havlir D, Eron J, Gonzalez C, McMahon D, et al. Potent and sustained antiretroviral activity of indinavir in combination with zidovudine and lamivudine [Abstract]. Third Conference on Retroviruses and Opportunistic Infections. Washington, DC: 1996:LB7.
6. Crixivan (indinavir sulfate) - U.S. package insert. West Point, PA: Merck & Co.; 1996.
7. Daudon M, Estépa L, Viard JP, Joy D, Jungers P. Urinary stones in HIV-1 positive patients treated with indinavir. Lancet. 1997;349:1294-5.
8. Tashima KT, Horowitz JD, Rosen S. Indinavir nephropathy [Letter]. N Engl J Med. 1997;336:138-9.
9. Patzelt W. Polarized Light Microscopy. Wetzlar, Germany: Ernst Leitz: 1974.
10. Dorsey BD, Levin RB, McDaniel SL, Vacca JP, Guare JP, Darke PL, et al. L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. J Med Chem. 1994;14:3443-51.
11. Birch DF, Fairley KF, Becker GJ, Kincaid-Smith P. A Color Atlas of Urine Microscopy. New York: Chapman & Hall; 1994.
12. Haber MH. Urinary Sediment: A Textbook Atlas. Chicago: American Society of Clinical Pathologists; 1981.
13. Lin JH, Chen IW, Vastag KJ, Ostovic D. pH-dependent oral absorption of I-735,524, a potent HIV protease inhibitor, in rats and dogs. Drug Metab Dispos. 1995;23:730-5.
14. Balani SH, Arison BH, Mathai L, Kauffman LR, Miller RR, Sterns RA, et al. Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine. Drug Metab Dispos. 1995;23:266-70.
15. Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. N Engl J Med. 1992;327:1141-52.
16. Preminger GM. Renal calculi: pathogenesis, diagnosis, and medical therapy. Semin Nephrol. 1992;12:200-16.
17. Rapado A, Traba ML, Caycho C, Cifuentes-Delatte L. Drug-induced renal stones: incidence, clinical expression and stone analysis. Contrib Nephrol. 1987;58:25-9
18. Sawyer MH, Webb DE, Balow JE, Straus SE. Acyclovir-induced renal failure. Clinical course and histology. Am J Med. 1988;84:1067-72.
19. Farina LA, Palou Redorta J, Chechile Toniolo G. Reversible acute renal failure due to sulfonamide-induced lithiasis in an AIDS patient. Arch Esp Urol. 1995;48:418-19.
20. McEvoy GK, ed. Drug Information. Bethesda, MD: American Society of Health-System Pharmacists; 1996.
21. Piscitelli SC, Flexner C, Minor JR, Polis MA, Masur H. Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis. 1996;23:685-93.